Publications

Annual reports

Read More

2021

  1. Alcindor T, Dumitra S, Albritton K, Thomas DM. Disparities in Cancer Care: The Example of Sarcoma-In Search of Solutions for a Global Issue. Am Soc Clin Oncol Educ Book. 2021 Mar;41:1-7. doi: 10.1200/EDBK_320463. PMID: 33770458.
  2. Bartley N, Best MC, Biesecker BB, Fisher A, Goldstein D, Meiser B, Thomas DM, Ballinger ML, Butow P. Effectively communicating comprehensive tumor genomic profiling results: Mitigating uncertainty for advanced cancer patients. Patient Educ Couns. 2021 May 14:S0738-3991(21)00347-5. doi: 10.1016/j.pec.2021.05.018. Epub ahead of print. PMID: 34016496.
  3. Bartley N, Davies G, Butow P, Napier CE, Schlub T, Ballinger ML, Thomas DM, Juraskova I, Meiser B, Best MC. Fear of cancer recurrence in patients undergoing germline genome sequencing. Support Care Cancer. 2021 May 25. doi: 10.1007/s00520-021-06311-9. Epub ahead of print. PMID: 34036439.
  4. Butow P, Davies G, Napier CE, Bartley N, Ballinger ML, Biesecker B, Juraskova I, Meiser B, Schlub T, Thomas DM, Goldstein D, Best MC; Members of the PiGeOn Project. Value of whole-genome sequencing to Australian cancer patients and their first-degree relatives participating in a genomic sequencing study. J Genet Couns. 2021 Jul 3. doi: 10.1002/jgc4.1455. Epub ahead of print. PMID: 34218500.
  5. Butow P, Müller F, Napier CE, Bartley N, Ballinger ML, B Biesecker B, Juraskova I, Meiser B, Schlub TE, Thomas DM, Goldstein D, Best M, Members of the PiGeOn Project. Longitudinal patterns in fear of cancer progression in patients with rare, advanced cancers undergoing comprehensive tumour genomic profiling. Psycho‐Oncology 2021 30 (11), 1920-1929. https://doi.org/10.1002/pon.5764
  6. Cilento MA, Poplawski NK, Paramasivam S, Thomas DM, Kichenadasse G. Germline PALB2 Variants and PARP Inhibitors in Endometrial Cancer. J Natl Compr Canc Netw. 2021 Nov;19(11):1212-1217. doi: 10.6004/jnccn.2021.7067. PMID: 34781271.
  7. Gong B, Li D, Kusko R, Novoradovskaya N, Zhang Y, Wang S, Pabón-Peña C, Zhang Z, Lai K, Cai W, LoCoco JS, Lader E, Richmond TA, Mittal VK, Liu LC, Johann DJ Jr, Willey JC, Bushel PR, Yu Y, Xu C, Chen G, Burgess D, Cawley S, Giorda K, Haseley N, Qiu F, Wilkins K, Arib H, Attwooll C, Babson K, Bao L, Bao W, Lucas AB, Best H, Bhandari A, Bisgin H, Blackburn J, Blomquist TM, Boardman L, Burgher B, Butler DJ, Chang CJ, Chaubey A, Chen T, Chierici M, Chin CR, Close D, Conroy J, Coleman JC, Craig DJ, Crawford E, Del Pozo A, Deveson IW, Duncan D, Eterovic AK, Fan X, Foox J, Furlanello C, Ghosal A, Glenn S, Guan M, Haag C, Hang X, Happe S, Hennigan B, Hipp J, Hong H, Horvath K, Hu J, Hung LY, Jarosz M, Kerkhof J, Kipp B, Kreil DP, Łabaj P, Lapunzina P, Li P, Li QZ, Li W, Li Z, Liang Y, Liu S, Liu Z, Ma C, Marella N, Martín-Arenas R, Megherbi DB, Meng Q, Mieczkowski PA, Morrison T, Muzny D, Ning B, Parsons BL, Paweletz CP, Pirooznia M, Qu W, Raymond A, Rindler P, Ringler R, Sadikovic B, Scherer A, Schulze E, Sebra R, Shaknovich R, Shi Q, Shi T, Silla-Castro JC, Smith M, López MS, Song P, Stetson D, Strahl M, Stuart A, Supplee J, Szankasi P, Tan H, Tang LY, Tao Y, Thakkar S, Thierry- Mieg D, Thierry-Mieg J, Thodima VJ, Thomas D, Tichý B, Tom N, Garcia EV, Verma S, Walker K, Wang C, Wang J, Wang Y, Wen Z, Wirta V, Wu L, Xiao C, Xiao W, Xu S, Yang M, Ying J, Yip SH, Zhang G, Zhang S, Zhao M, Zheng Y, Zhou X, Mason CE, Mercer T, Tong W, Shi L, Jones W, Xu J. Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions. Genome Biol. 2021 Apr 16;22(1):109. doi: 10.1186/s13059-021-02315-0. PMID: 33863344; PMCID: PMC8051090.
  8. Jadhao S, Davison C, Roulis E, Lee S, Lacaze P, Riaz M, McNeil JJ, Thomas DM, Pecheniuk NM, Hyland CA, Flower RL, Nagaraj S, Using Whole Genome Sequencing to Characterize Clinically Significant Blood Groups Among Healthy Older Australians. medRxiv 2021.04.18.21255241; doi: https://doi.org/10.1101/2021.04.18.21255241
  9. Kaur S, Sikta N, Schafferhans A, Bordin N, Cowley MJ, Thomas DM, Ballinger ML, O’Donoghue SL., Streamlined use of protein structures in variant analysis. bioRxiv 2021.09.10.459756; doi: https://doi.org/10.1101/2021.09.10.459756
  10. Lau LMS, Mayoh C, Xie J, Barahona P, MacKenzie KL, Wong M, Kamili A, Tsoli M, Failes TW, Kumar A, Mould EVA, Gifford A, Chow SO, Pinese M, Fletcher JI, Arndt GM, Khuong-Quang DA, Wadham C, Eden G, Trebilcock P, Joshi S, Alfred S, Gopalakrishnan A, Khan A, Grebert Wade D, Strong PA, Manouvrier E, Morgan LT, Cadiz R, Ung C, Thomas DM, Tucker KM, Warby M, McCowage GB, Dalla-Pozza L, Byrne JA, Saletta F, Fellowes A, Fox SB, Norris MD, Tyrrell V, Trahair TN, Lock RB, Cowley MJ, Ekert PG, Haber M, Ziegler DS, Marshall GM. In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer. EMBO Mol Med. 2021 Dec 20:e14608. doi: 10.15252/emmm.202114608. Epub ahead of print. PMID: 34927798.
  11. Lin FP, Thavaneswaran S, Grady JP, Ballinger M, Kansara M, Oakes SR, Desai J, Lee CK, Simes J, Thomas DM. Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology. NPJ Precis Oncol. 2021 Jun 23;5(1):58. doi: 10.1038/s41698-021-00194-z. PMID: 34162978.
  12. Meiser B, Butow P, Davies G, Napier CE, Schlub TE, Bartley N, Juraskova I, Ballinger ML, Thomas DM, Tucker K, Goldstein D, Biesecker BB, Best MC; Members of the Psychosocial Issues in Genomics in Oncology (PiGeOn) Project. Psychological predictors of advanced cancer patients’ preferences for return of results from comprehensive tumor genomic profiling. Am J Med Genet A. 2021 Nov 10. doi: 10.1002/ajmg.a.62563. Epub ahead of print. PMID: 34755933.
  13. Minoche AE, Lundie B, Peters GB, Ohnesorg T, Pinese M, Thomas DM, Zankl A, Roscioli T, Schonrock N, Kummerfeld S, Burnett L, Dinger ME, Cowley MJ. ClinSV: clinical grade structural and copy number variant detection from whole genome sequencing data. Genome Med. 2021 Feb 25;13(1):32. doi: 10.1186/s13073-021-00841-x. PMID: 33632298; PMCID: PMC7908648.
  14. Mweempwa A, Xu H, Vissers JHA, Tothill RW, Pattison AD, Fellowes AP, Thomas DM, Richardson G, Hicks RJ, Grimmond SM, Fox SB, Luen SJ, Desai J, Solomon BJ. Novel RET Fusion RET-SEPTIN9Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma. JCO Precis Oncol. 2021 Nov;5:1160-1165. doi: 10.1200/PO.21.00127. PMID: 34994633.
  15. Napier CE, Davies G, Butow PN, Schlub TE, Best MC, Bartley N, Juraskova I, Meiser B, Tucker KM, Biesecker BB, Thomas DM, Ballinger ML; Members of the PiGeOn Project. Cancer patient knowledge about and behavioral intentions after germline genome sequencing. Patient Educ Couns. 2021 Jul 7:S0738-3991(21)00439-0. doi: 10.1016/j.pec.2021.07.004. Epub ahead of print. PMID: 34247865.
  16. Sabesan S, Malica M, Gebbie C, Scott C, Thomas D, Zalcberg J. Implementation of the Australasian Teletrial Model: Translating idea into action using implementation science frameworks. J Telemed Telecare. 2021 Jul 7:1357633X211017805. doi: 10.1177/1357633X211017805. Epub ahead of print. PMID: 34233548.
  17. Scheinberg T, Lomax A, Tattersall M, Thomas D, McCowage G, Sullivan M, Karim R, Luk PP, Mahar A, Bonar F, Bhadri VA. PD-1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma. Cancer Rep (Hoboken). 2021 Apr;4(2):e1327. doi: 10.1002/cnr2.1327. Epub 2020 Dec 13. PMID: 33314769.
  18. Singhal D, Hahn CN, Feurstein S, Wee LYA, Moma L, Kutyna MM, Chhetri R, Eshraghi L, Schreiber AW, Feng J, Wang PP, Babic M, Parker WT, Gao S, Moore S, Das S, Thomas D, Pattnaik S, Brown AL, D’Andrea RJ, Poplawski NK, Thomas D, Scott HS, Godley LA, Hiwase DK. Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. Leukemia. 2021 Apr 13. doi: 10.1038/s41375-021-01246-w. Epub ahead of print. PMID: 33850299.
  19. Smit AK, Bartley N, Best MC, Napier CE, Butow P, Newson AJ, Tucker K, Ballinger ML, Thomas DM, Jacobs C, Meiser B, Goldstein D, Savard J, Juraskova I; PiGeOn authorship group. Family communication about genomic sequencing: A qualitative study with cancer patients and relatives. Patient Educ Couns. 2021 May;104(5):944-952. doi: 10.1016/j.pec.2020.10.022. Epub 2020 Oct 20. PMID: 33129629.
  20. Stacchiotti S, Frezza AM, Blay JY, Baldini EH, Bonvalot S, Bovée JVMG, Callegaro D, Casali PG, Chiang RC, Demetri GD, Demicco EG, Desai J, Eriksson M, Gelderblom H, George S, Gounder MM, Gronchi A, Gupta A, Haas RL, Hayes-Jardon A, Hohenberger P, Jones KB, Jones RL, Kasper B, Kawai A, Kirsch DG, Kleinerman ES, Le Cesne A, Lim J, Chirlaque López MD, Maestro R, Marcos-Gragera R, Martin Broto J, Matsuda T, Mir O, Patel SR, Raut CP, Razak ARA, Reed DR, Rutkowski P, Sanfilippo RG, Sbaraglia M, Schaefer IM, Strauss DC, Sundby Hall K, Tap WD, Thomas DM, van der Graaf WTA, van Houdt WJ, Visser O, von Mehren M, Wagner AJ, Wilky BA, Won YJ, Fletcher CDM, Dei Tos AP, Trama A. Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer127(16), 2934–2942. https://doi.org/10.1002/cncr.33618 Apr 28. doi: 10.1002/cncr.33618. Epub ahead of print. PMID: 33910263.
  21. Sylvester DE, Chen Y, Grima N, Saletta F, Padhye B, Bennetts B, Wright D, Krivanek M, Graf N, Zhou L, Catchpoole D, Kirk J, Latchoumanin O, Qiao L, Ballinger M, Thomas D, Jamieson R, Dalla-Pozza L, Byrne JA. Rare germline variants in childhood cancer patients suspected of genetic predisposition to cancer. Genes Chromosomes Cancer. 2022 Feb;61(2):81-93. doi: 10.1002/gcc.23006. Epub 2021 Oct 30. PMID: 34687117.
  22. Thavaneswaran, S., Ballinger, M., Butow, P., Meiser, B., Goldstein, D., Lin, F., Napier, C., Thomas, D., & Best, M. (2021). The experiences and needs of Australian medical oncologists in integrating comprehensive genomic profiling into clinical care: a nation-wide survey. Oncotarget12(21), 2169–2176. https://doi.org/10.18632/oncotarget.28076
  23. Thomas DM, Hackett JM, Plestina S. Unlocking Access to Broad Molecular Profiling: Benefits, Barriers, and Policy Solutions. Public Health Genomics. 2021 Dec 27:1-10. doi: 10.1159/000520000. Epub ahead of print. PMID: 34959236.
  24. Vatter S, Bartley, Nicci MA, Best M, Juraskova I, Jacobs C, Ballinger ML, Thomas DM, Butow, P. Does undertaking genome sequencing prompt actual and planned lifestyle-related behavior change in cancer patients and survivors? A qualitative study, Journal of Psychosocial Oncology Research and Practice: July-September 2021 – Volume 3 – Issue 3 – p e059 doi: 10.1097/OR9.0000000000000059
  25. Willis AM, Smith SK, Meiser B, James PA, Ballinger ML, Thomas DM, Yanes T, Young MA. Influence of lived experience on risk perception among women who received a breast cancer polygenic risk score: ‘Another piece of the pie’. J Genet Couns. 2021 Jun;30(3):849-860. doi: 10.1002/jgc4.1384. Epub 2021 Jan 19. PMID: 33470033.

2020

  1. Seung Jun Shin, Elissa Dodd-Eaton, Gang Peng, Jasmina Bojadzieva, Jingxiao Chen, Christopher Amos, Megan Frone, Payal Khincha, Phuong Mai, Sharon Savage, Mandy Ballinger, David Thomas, Ying Yuan, Louise Strong, and Wenyi Wang (2020). Penetrance of different cancer types in families with Li-Fraumeni syndrome: a validation study using multi-center cohorts. Cancer Research 80:354–60
  2. Mirabello L, Zhu B, Koster R, Karlins E, Dean M, Yeager M, Gianferante M, Spector LG, Morton LM, Karyadi D, Robison LL, Armstrong GT, Bhatia S, Song L, Pankratz N, Pinheiro M, Gastier-Foster JM, Gorlick R, de Toledo SRC, Petrilli AS, Patino-Garcia A, Lecanda F, Gutierrez-Jimeno M, Serra M, Hattinger C, Picci P, Scotlandi K, Flanagan AM, Tirabosco R, Amary MF, Kurucu N, Ilhan IE, Ballinger ML, Thomas DM, Barkauskas DA, Mejia-Baltodano G, Valverde P, Hicks BD, Zhu B, Wang M, Hutchinson AA, Tucker M, Sampson J, Landi MT, Freedman ND, Gapstur S, Carter B, Hoover RN, Chanock SJ, Savage SA. Pathogenic germline variants in cancer-susceptibility genes in osteosarcoma patients. JAMA Oncology 2020 6: 724-734
  3. Bartley N, Best M, Jacobs C, Juraskova I, Newson A, Savard J, Meiser B, Ballinger ML, Thomas DM, Biesecker B, Butow P. Cancer patients’ views and understanding of genome sequencing: a qualitative study. J Med Genet 2020 in press.
  4. Butow P, Davies G, Napier C, Bartley N, Juraskova I, Meiser B, Ballinger ML, Schlub T, Thomas DM, Goldstein D, Best MC and members of the PiGeOn Project. Value of Tumor Mutation Profiling to Cancer Patients: An Investigation using the Willingness-To-Pay Technique. JAMA Network Open 2020 3: e204721.
  5. Davies G, Butow P, Napier CE, Bartley, N, Juraskova I, Meiser B, Ballinger ML, Thomas DM, Schlub TE, Best M. 2020. Advanced cancer patient knowledge of and attitudes towards tumor molecular profiling. Translational Oncology 13: 100799.
  6. Kalachand RD, Stordal B, Madden S, Chandler B, Cunningham J, Goode EL, Ruscito I, Braicu EI, Sehouli J, Ignatov A, Yu H, Katsaros D, Mills GB, Lu KH, Carey MS, Timms KM, Kupryjanczyk J, Rzepecka IK, Podgorska A, McAlpine JN, Swisher EM, Bernards SS, O’Riain C, O’Toole S, O’Leary JJ, Bowtell DD, Thomas DM, Prieske K, Joosse SA, Woelber L, Chaudhry P, Häfner N, Runnebaum IB, Hennessy BT. BRCA1 promoter methylation and clinical outcomes in ovarian cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2020 May 15:djaa070. doi: 10.1093/jnci/djaa070.
  7. Kovac M, Woolley C, Ribi S, Blattmann C, Roth E, Morini M, Kovacova M, Ameline B, Kulozik A, Bielack S, Hartmann W, Ballinger ML, Thomas DM, Tomlinson I, Nathrath M, Heinimann K, Baumhoer D.J Germline RETvariants underlie a subset of paediatric osteosarcoma. Med Genet. 2020 Mar 16:jmedgenet-2019-106734. doi: 10.1136/jmedgenet-2019-106734. Online ahead of print.
  8. Dancsok AR, Gao D, Lee AF, Steigen SE, Blay JY, Thomas DM, Maki RG, Nielsen TO, Demicco EG. Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas. Oncoimmunology. 2020 Apr 12;9(1):1747340. doi: 10.1080/2162402X.2020.1747340.
  9. Shin SJ, Dodd-Eaton EB, Peng G, Bojadzieva J, Chen J, Amos CI, Frone MN, Khincha PP, Mai PL, Savage SA, Ballinger ML, Thomas DM, Yuan Y, Strong LC, Wang W.Penetrance of Different Cancer Types in Families with Li-Fraumeni Syndrome: A Validation Study Using Multicenter Cohorts. Cancer Res. 2020 Jan 15;80(2):354-360. doi: 10.1158/0008-5472.CAN-19-0728. Epub 2019 Nov 12.
  10. Best MC, Butow P, Jacobs C, Savard J, Biesecker B, Ballinger ML, Bartley N, Davies G, Napier CE, Smit AK, Thomas DM, Newson AJ. Members of the PiGeOn Project.Who should access germline genome sequencing? A mixed methods study of patient views. Clin Genet. 2020 Feb;97(2):329-337. doi: 10.1111/cge.13664. Epub 2019 Nov 26.
  11. Caron O, Thomas DM, World Health Organisation Classification of Tumours – Thoracic Tumours, 5th Edition, Li Fraumeni Syndrome, 2020, In press (book chapter)
  12. Cipponi A, Goode DL, Bedo J, McCabe MJ, Pajic M, Gonzalez-Rajal A, Croucher DR, Junankar S, Saunders DN, Lobachevsky P, Papenfuss AT, Nessem D, Nobis M, Warren SC, Timpson P, Cowley M, Vargas AC, Qiu MR, Generali DG, Keerthikumar S, Nguyen U, Corcoran NM, Long GV, Blay J-Y, Thomas DM. MTOR signaling orchestrates stress-induced mutagenesis facilitating adaptive evolution in human cancers. Science 2020 368: 1127-1131. [IF – 41.06]
  13. Best M, Butow P, Jacobs C, Juraskova I, Savard J, Meiser B, Goldstein D, Ballinger ML, Bartley N, Napier C, Davies G, Thomas DM, Tucker K, Schlub T, Newson AJ and members of the PiGeOn Project. Advanced cancer patient preferences for receiving molecular profiling results. Psycho-Oncology 2020 16 June 2020 doi: 10.1002/pon.5446
  14. Pinese M, Lacaze P, Rath EM, Stone A, Brion MJ, Ameur A, Nagpal S, Puttick C, Husson S, Degrave D, Cristina TN, Kahl VFS, Statham AL, Woods RL, McNeil JJ, Riaz M, Barr M, Nelson MR, Reid CM, Murray AM, Shah R.C, Wolfe R, Atkins JR, Fitzsimmons C, Cairns HM, Green MJ, Carr VJ, Cowley MJ, Pickett HA, James PA, Powell JE, Kaplan W, Gibson G, Gyllensten U, Cairns MJ, McNamara M, Dinger ME, Thomas DM. 2020 The Medical Genome Reference Bank contains whole genome and phenotype data of 2570 healthy elderly. Nat Commun, 11: 435

2019

  1. Malkin D, Bond G, Thomas DM, Ballinger ML, World Health Organisation Classification of Tumours – Soft Tissue and Bone 5th edition, 2019. Li Fraumeni Syndrome.
  2. Ballinger ML, Pinese M and Thomas DM (2019). Translating genomic risk into an early detection strategy for sarcoma. Genes Chromosomes Cancer 58: 130-136.
  3. Fortuno C, Cipponi A, Ballinger ML, Tavtigian SV, Olivier M, Ruparel V, Haupt Y, Haupt S, Study ISK, Tucker K, Spurdle AB, Thomas DM and James PA (2019). A quantitative model to predict pathogenicity of missense variants in the TP53 gene. Hum Mutat 40: 788-800.
  4. Heyer EE, Deveson IW, Wooi D, Selinger CI, Lyons RJ, Hayes VM, O’Toole SA, Ballinger ML, Gill D, Thomas DM, Mercer TR and Blackburn J (2019). Diagnosis of fusion genes using targeted RNA sequencing. Nat Commun 10: 1388.
  5. Jones RM, Melton PE, Pinese M, Rea AJ, Ingley E, Ballinger ML, Wood DJ, Thomas DM and Moses EK (2019). Identification of novel sarcoma risk genes using a two-stage genome wide DNA sequencing strategy in cancer cluster families and population case and control cohorts. BMC Med Genet 20: 69.
  6. Lacaze P, Pinese M, Kaplan W, Stone A, Brion MJ, Woods RL, McNamara M, McNeil JJ, Dinger ME and Thomas DM (2019). The Medical Genome Reference Bank: a whole-genome data resource of 4000 healthy elderly individuals. Rationale and cohort design. European Journal of Human Genetics 27: 308-316.
  7. McCabe MJ, Pinese M, Chan CL, Sheriff N, Thompson TJ, Grady J, Wong M, Gauthier MA, Puttick C, Gayevskiy V, Hajdu E, Wong SQ, Barrett W, Earls P, Lukeis R, Cheng YY, Lin RCY, Thomas DM, Watkins DN, Dinger ME, McCormack AI and Cowley MJ (2019). Genomic stratification and liquid biopsy in a rare adrenocortical carcinoma (ACC) case, with dual lung metastases. Cold Spring Harb Mol Case Stud 5: pii: a003764.
  8. Thavaneswaran S, Rath E, Tucker K, Joshua AM, Hess D, Pinese M, Ballinger ML and Thomas DM (2019). Therapeutic implications of germline genetic findings in cancer. Nat Rev Clin Oncol 16: 386-396.
  9. Best MC, Bartley N, Jacobs C, Juraskova I, Goldstien D, Newson AJ, Savard J, Meiser B, Ballinger ML, Napier C, Thomas DM, Biesecker B, Butow P and members of the PiGeOn Project (2019). Patient perspectives on molecular tumour profiling: “Why wouldn’t you?”. BMC Cancer 19:753.
  10. Kansara, M., Thomson, K., Pang, P., Dutour, A., Mirabello, L., Acher, F., Pin, J.P., Demicco, E.G., Yan, J., Teng, M.W.L., Smyth, M.J., Thomas, D.M. (2019). Infiltrating myeloid cells drive osteosarcoma progression via GRM4 regulation of IL23. Cancer Discov, 9: 1511-1519.
  11. Vargas, A.C., Selinger, C., Satgunaseelan, L., Cooper, W.A., Gupta, R., Stalley, P., Brown, W., Soper, J., Schatz, J., Boyle, R., Thomas, D.M., Tattersall, M.H.N., Bhadri, V., Maclean, F., Bonar, S.F., Scolyer, R.A., Karim, R.Z., McCarthy, S.W., Mahar, A., O’Toole, S.A. (2019). FISH analysis of selected soft tissue tumors: Diagnostic experience in a tertiary center. Asia Pac J Clin Oncol, 15: 38-47.
  12. Yanes T, Willis AM, Meiser B, Tucker KM, Best M. (2019). Psychological and behavioural outcomes of genomic testing in cancer: a systematic review. European Journal of Human Genetics; 27 : 28-35.

2018

  1. Lacaze, P., Pinese, M., Kaplan, W., Stone, A., Brion, M.J., Woods, R.L., McNamara, M., McNeil, J.J., Dinger, M.E., Thomas, D.M. 2018 The Medical Genome Reference Bank: a whole-genome data resource of 4000 healthy elderly individuals. Rationale and cohort design. Eur J Hum Genet, doi: 10.1038/s41431- 41018-40279-z.
  2. Best, M., Newson, A.J., Meiser, B., Juraskova, I., Goldstein, D., Tucker, K., Ballinger, M.L., Hess, D., Schlub, T.E., Biesecker, B., Vines, R., Vines, K., Thomas, D., Young, M.A., Savard, J., Jacobs, C., Butow, P. 2018 The PiGeOn project: protocol for a longitudinal study examining psychosocial, behavioural and ethical issues and outcomes in cancer tumour genomic profiling. BMC Cancer, 18: 389.
  3. Best, M., Newson, A.J., Meiser, B., Juraskova, I., Goldstein, D., Tucker, K., Ballinger, M.L., Hess, D., Schlub, T.E., Biesecker, B., Vines, R., Vines, K., Thomas, D., Young, M.A., Savard, J., Jacobs, C., Butow, P. 2018 The PiGeOn project: protocol of a longitudinal study examining psychosocial and ethical issues and outcomes in germline genomic sequencing for cancer. BMC Cancer, 18: 454.
  4. Chou, A., Froio, D., Nagrial, A.M., Parkin, A., Murphy, K.J., Chin, V.T., Wohl, D., Steinmann, A., Stark, R., Drury, A., Walters, S.N., Vennin, C., Burgess, A., Pinese, M., Chantrill, L.A., Cowley, M.J., Molloy, T.J., Waddell, N., Johns, A., Grimmond, S.M., Chang, D.K., Biankin, A.V., Sansom, O.J., Morton, J.P., Grey, S.T., Cox, T.R., Turchini, J., Samra, J., Clarke, S.J., Timpson, P., Gill, A.J., Pajic, M. 2018 Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Gut, 67: 2142-2155.
  5. Gounder, M.M., Thomas, D.M., Tap, W.D. 2018 Locally aggressive connective tissue tumors. J Clin Oncol, 36: 202-209.
  6. Koster, R., Panagiotou, O.A., Wheeler, W.A., Karlins, E., Gastier-Foster, J.M., Caminada de Toledo, S.R., Petrilli, A.S., Flanagan, A.M., Tirabosco, R., Andrulis, I.L., Wunder, J.S., Gokgoz, N., Patino-Garcia, A., Lecanda, F., Serra, M., Hattinger, C., Picci, P., Scotlandi, K., Thomas, D.M., Ballinger, M.L., Gorlick, R., Barkauskas, D.A., Spector, L.G., Tucker, M., Belynda, D.H., Yeager, M., Hoover, R.N., Wacholder, S., Chanock, S.J., Savage, S.A., Mirabello, L. 2018 Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients. Int J Cancer, 142: 1594-1601.
  7. Rasmussen, V., Forrest, L.E., Rogasik, M., Girodet, M., Meeus, P., Sunyach, M.P., Blay, J.Y., Bally, O., Brahmi, M., Ballinger, M.L., Niedermayr, E., Thomas, D.M., Halliday, J., James, P., Ray-Coquard, I., Young, M.A., International Sarcoma Kindred, S. 2018 A comparison of Australian and French families affected by sarcoma: perceptions of genetics and incidental findings. Per Med, 15: 13-24.
  8. Thavaneswaran, S., Sebastian, L., Ballinger, M., Best, M., Hess, D., Lee, C.K., Sjoquist, K.M., Hague, W.E., Butow, P.N., Simes, R.J., Thomas, D. 2018 Cancer Molecular Screening and Therapeutics (MoST): a framework for multiple, parallel signal-seeking studies of targeted therapies for rare and neglected cancers. Med J Aust, 209: 354-355.
  9. Walczak, A., Patterson, P., Thomas, D. 2018 Trials and tribulations: improving outcomes for adolescents and young adults with rare and low survival cancers. Med J Aust, 209: 330-332.
  10. Woodcock, F., Doble, B., Cancer 2015 Consortium*. 2018 Mapping the EORTC-QLQ-C30 to the EQ- 5D-3L: An Assessment of Existing and Newly Developed Algorithms. Med Decis Making, 38: 954-967. (*D Thomas Chief Investigator)
  11. Zilberg, C., Lee, M.W., Yu, B., Ashford, B., Kraitsek, S., Ranson, M., Shannon, K., Cowley, M., Iyer, N.G., Palme, C.E., Ch’ng, S., Low, T.H., O’Toole, S., Clark, J.R., Gupta, R. 2018 Analysis of clinically relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma. Mod Pathol, 31: 275-287.

2017

  1. Ballinger, M.L., Best, A., Mai, P.L., Khincha, P.P., Loud, J.T., Peters, J.A., Achatz, M.I., Chojniak, R., Balieiro da Costa, A., Santiago, K.M., Garber, J., O’Neill, A.F., Eeles, R.A., Evans, D.G., Bleiker, E., Sonke, G.S., Ruijs, M., Loo, C., Schiffman, J., Naumer, A., Kohlmann, W., Strong, L.C., Bojadzieva, J., Malkin, D., Rednam, S.P., Stoffel, E.M., Koeppe, E., Weitzel, J.N., Slavin, T.P., Nehoray, B., Robson, M., Walsh, M., Manelli, L., Villani, A., Thomas, D.M., Savage, S.A. 2017 Baseline surveillance in Li-Fraumeni syndrome using whole-body magnetic resonance imaging: a meta-analysis. JAMA Oncol, 3: 1634-1639.
  2. Ballinger, M.L., Ferris, N.J., Moodie, K., Mitchell, G., Shanley, S., James, P.A., Thomas, D.M. 2017 Surveillance in germline TP53 mutation carriers utilizing whole-body magnetic resonance imaging. JAMA Oncol, 3: 1735-1736.
  3. Cho, D., Roncolato, F.T., Man. J., Simes, J., Lord, S.J., Links, M.J., Lee, C.K. 2017 Clinical equipoise for trials of novel biological therapies, therapeutic success rates and predictors of success: a meta-analysis. JCO Prec Oncol 1:1-12
  4. Doble, B., John, T., Thomas, D., Fellowes, A., Fox, S., Lorgelly, P. 2017 Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing. Lung Cancer, 107: 22-35.
  5. Fleuren, E.D.G., Vlenterie, M., van der Graaf, W., Hillebrandt-Roeffen, M.H.S., Blackburn, J., Ma, X., Chan, H., Magias, M.C., van Erp, A., van Houdt, L., Cebeci, S., van de Ven, A., Flucke, U.E., Heyer, E.E., Thomas, D.M., Lord, C.J., Marini, K.D., Vaghjiani, V., Mercer, T., Cain, J.E., Wu, J., Versleijen-Jonkers, Y.M.H., Daly, R.J. 2017 Phosphoproteomic profiling reveals ALK and MET as novel actionable targets across synovial sarcoma subtypes. Cancer Res, 77: 4279-4292.
  6. Khoo, T.K., Yu, B., Smith, J.A., Clarke, A.J., Luk, P.P., Selinger, C.I., Mahon, K.L., Kraitsek, S., Palme, C., Boyer, M.J., Dinger, M.E., Cowley, M.J., O’Toole, S.A., Clark, J.R., Gupta, R. 2017 Somatic mutations in salivary duct carcinoma and potential therapeutic targets. Oncotarget, 8: 75893-75903.
  7. Leroy, B., Ballinger, M.L., Baran-Marszak, F., Bond, G.L., Braithwaite, A., Concin, N., Donehower, L.A., El-Deiry, W.S., Fenaux, P., Gaidano, G., Langerod, A., Hellstrom-Lindberg, E., Iggo, R., Lehmann-Che, J., Mai, P.L., Malkin, D., Moll, U.M., Myers, J.N., Nichols, K.E., Pospisilova, S., Ashton-Prolla, P., Rossi, D., Savage, S.A., Strong, L.C., Tonin, P.N., Zeillinger, R., Zenz, T., Fraumeni, J.F., Jr., Taschner, P.E., Hainaut, P., Soussi, T. 2017 Recommended guidelines for validation, quality control, and reporting of TP53 variants in clinical practice. Cancer Res, 77: 1250-1260.
  8. Lorgelly, P.K., Doble, B., Rowen, D., Brazier, J., Cancer 2015 Investigators*. 2017 Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L. Qual Life Res, 26: 1163-1176. (*D Thomas Chief Investigator)
  9. McBride, K.A., Ballinger, M.L., Schlub, T.E., Young, M.A., Tattersall, M.H., Kirk, J., Eeles, R., Killick, E., Walker, L.G., Shanley, S., Thomas, D.M., Mitchell, G. 2017 Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial? Fam Cancer, 16: 423-432.
  10. Peng, G., Bojadzieva, J., Ballinger, M.L., Li, J., Blackford, A.L., Mai, P.L., Savage, S.A., Thomas, D.M., Strong, L.C., Wang, W. 2017 Estimating TP53 mutation carrier probability in families with Li-Fraumeni syndrome using LFSPRO. Cancer Epidemiol Biomarkers Prev, 26: 837-844.
  11. Takeda, K., Nakayama, M., Hayakawa, Y., Kojima, Y., Ikeda, H., Imai, N., Ogasawara, K., Okumura, K., Thomas, D.M., Smyth, M.J. 2017 IFN-gamma is required for cytotoxic T cell-dependent cancer genome immunoediting. Nat Commun, 8: 14607.
  12. Thomas, D.M. 2017 Is Li-Fraumeni syndrome really much more common? Hum Mutat, 38: 1619.
  13. Thomas, D.M., Whelan, J. in Cancer in Adolescents and Young Adults. Pediatric Oncology (eds. Bleyer, A., Barr, R., Ries, L., Whelan, J. & Ferrari, A.) 417-427 (Springer International Publishing, 2017).
  14. Warton, K., Yuwono, N.L., Cowley, M.J., McCabe, M.J., So, A., Ford, C.E. 2017 Evaluation of Streck BCT and PAXgene stabilised blood collection tubes for cell-free circulating DNA studies in plasma. Mol Diagn Ther, 21: 563-570.
  15. Willis, A.M., Smith, S.K., Meiser, B., Ballinger, M.L., Thomas, D.M., Young, M.A. 2017 Sociodemographic, psychosocial and clinical factors associated with uptake of genetic counseling for hereditary cancer: a systematic review. Clin Genet, 92: 121-133.